- Home
- IMRN vs GOVX Comparison
IMRN vs GOVX Comparison
Compare IMRN & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMRN
- GOVX
- Stock Information
- Founded
- IMRN 1994
- GOVX 2001
- Country
- IMRN Australia
- GOVX United States
- Employees
- IMRN N/A
- GOVX N/A
- Industry
- IMRN Biotechnology: Pharmaceutical Preparations
- GOVX Biotechnology: Pharmaceutical Preparations
- Sector
- IMRN Health Care
- GOVX Health Care
- Exchange
- IMRN Nasdaq
- GOVX Nasdaq
- Market Cap
- IMRN 9.2M
- GOVX 7.6M
- IPO Year
- IMRN N/A
- GOVX N/A
- Fundamental
- Price
- IMRN $1.81
- GOVX $0.76
- Analyst Decision
- IMRN Strong Buy
- GOVX Strong Buy
- Analyst Count
- IMRN 1
- GOVX 4
- Target Price
- IMRN $5.00
- GOVX $10.50
- AVG Volume (30 Days)
- IMRN 82.1K
- GOVX 1.2M
- Earning Date
- IMRN 09-08-2025
- GOVX 07-28-2025
- Dividend Yield
- IMRN N/A
- GOVX N/A
- EPS Growth
- IMRN N/A
- GOVX N/A
- EPS
- IMRN N/A
- GOVX N/A
- Revenue
- IMRN $4,048,286.00
- GOVX $6,143,044.00
- Revenue This Year
- IMRN N/A
- GOVX N/A
- Revenue Next Year
- IMRN N/A
- GOVX N/A
- P/E Ratio
- IMRN N/A
- GOVX N/A
- Revenue Growth
- IMRN 82.90
- GOVX 1943.07
- 52 Week Low
- IMRN $1.50
- GOVX $0.43
- 52 Week High
- IMRN $2.87
- GOVX $11.18
- Technical
- Relative Strength Index (RSI)
- IMRN 58.51
- GOVX 51.62
- Support Level
- IMRN $1.62
- GOVX $0.66
- Resistance Level
- IMRN $1.84
- GOVX $0.75
- Average True Range (ATR)
- IMRN 0.09
- GOVX 0.05
- MACD
- IMRN 0.02
- GOVX 0.01
- Stochastic Oscillator
- IMRN 89.55
- GOVX 62.30
About IMRN Immuron Limited
Immuron Ltd is a commercial and clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company's product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.
About GOVX GeoVax Labs Inc.
Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.